Life Sciences Large Investment Portfolio
Published 21 August 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/life-sciences-large-investment-portfolio/life-sciences-large-investment-portfolio
The Life Sciences Large Investment Portfolio (LSLIP) – launched on 14 April 2026 – is a key commitment in the Government’s Life Sciences Sector Plan. It is designed to attract high-value manufacturing and research and development (R&D) investment portfolios to the UK.
If you are developing a portfolio of manufacturing or R&D projects, LSLIP may help you access government support and explore potential funding opportunities.
Check if you’re eligible
To be eligible for the LSLIP scheme, companies must meet the following requirements:
Business registration and sector
Companies must be UK-registered or a UK-registered establishment.
UK-registered establishments must also:
- have at least one UK-registered company within their group structure
- be wholly private-sector
- operate in the medicines, MedTech, or diagnostics sector
- possess all necessary regulatory approvals
Investment commitment
Companies must commit to investing at least £250 million over 3 years in UK life sciences manufacturing or R&D, with at least one eligible project starting within the next 12 months.
Financial standing
Companies must:
- have 3 years of audited financial statements (for the member company or parent entity) and commit, including through the provision of securities from a parent company (which may be the ultimate parent, UK parent, or holding parent)
- provide acceptable protection of public funds for any grants awarded under the scheme
Financial transparency
Companies must have financial and corporate information that can be readily validated through audited accounts and other publicly available disclosures. Companies with publicly listed parent entities, or equivalent reporting obligations, may be particularly well placed to support a streamlined and proportionate due diligence process.
Proven track record
Companies must demonstrate a history of successfully developing or manufacturing medicines or medical devices in the UK or internationally.
Who to contact
If you think you are eligible and would like to find out more, please email: LSLIP@officeforlifesciences.gov.uk
Capital support for standalone investments or those under £250 million
For manufacturing investment projects over £8 million, you may want to consider the Life Sciences Innovative Manufacturing Fund (LSLIP).
Learn more at the Find a grant website.
For R&D investment projects exceeding £100 million, the Life Sciences Transformational R&D Investment Fund (TRIF) could be relevant.
More details are available at the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot page